News

Reata Stops Bardoxolone PAH Trials Amid COVID-19 Concerns

Reata Pharmaceuticals is stopping clinical trials evaluating bardoxolone methyl in people with pulmonary arterial hypertension (PAH), including a Phase 3 study, to ensure the safety of participants during the COVID-19 pandemic, the company announced. Trials in other disorders are set to continue, although some will stop…

Immunosuppressives Seen to Aid SSc-PAH Patient with Rare Antibody

A 62-year-old with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) was successfully treated with immunosuppressants and vasodilators, a case study reports. The unusual antibody linked to her disease, called the anticentriole antibody, may also serve as a marker for the use of immunosuppressives in SSc-PAH patients with this antibody. The…

Orenitram Tablets More Cost-effective Than Uptravi as PAH Treatment, Study Suggests

Treatment with Orenitram (oral treprostinil) is associated with lower healthcare-related costs than treatment with Uptravi (selexipag) in people with pulmonary arterial hypertension (PAH), a new study suggests. The study, “Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective…